Peptide Advertising Compliance: The 2026 Guide

What laws govern peptide advertising in the US?

Three sets of rules apply at once, and they ask different questions. FDA asks whether the product is an unapproved drug, judged from how it is marketed. The FTC asks whether the advertising is truthful and substantiated. Ad platforms and payment networks then apply private rules.

On the FDA side, the Federal Food, Drug, and Cosmetic Act supplies four sections that appear again and again in peptide enforcement.

Section	What it does
21 U.S.C. § 355	A "new drug" may not be shipped in interstate commerce without an FDA-approved application.
21 U.S.C. § 331	Lists prohibited acts, including shipping an adulterated or misbranded drug (a) and shipping a drug in violation of § 355 (d).
21 U.S.C. § 352	Defines misbranding, including false or misleading labeling (a), no adequate directions for use (f), and false or misleading advertising of a compounded drug (bb).
21 U.S.C. § 333	Criminal and civil penalties. A § 331 violation is a misdemeanor (up to one year). A repeat violation, or one committed with intent to defraud or mislead, is a felony (up to three years).

On the FTC side, Section 5 of the FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce, and Section 12 makes it unlawful to disseminate false advertisements for food, drugs, devices, services or cosmetics. Those statutes, and FTC orders, are what bind. The FTC's Health Products Compliance Guidance is staff guidance, and the Endorsement Guides are administrative interpretations. Both explain how the FTC reads the law, and this guide quotes them as guidance, not as statute.

How does FDA decide whether a peptide is being sold as a drug?

FDA looks at intended use, and intended use comes from the seller's conduct, not the seller's label. Under 21 C.F.R. § 201.128, intent "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," including "labeling claims, advertising matter, or oral or written statements."

That is why a "Research Use Only" label fails. FDA's "Research Use Only" labeling rule for diagnostics, 21 C.F.R. § 809.10(c), covers in vitro diagnostic products. No FDA regulation lets a research label override the intended-use evidence. No FDA or FTC rule sets a type size or format that would turn such a statement into protection.

What the 2024 to 2026 warning letters show

The letters share a pattern: FDA finds the products are unapproved new drugs under § 355(a), says shipping them violates § 331(d), and says the research labeling did not change the result. The 2025 and 2026 letters also cite § 201.128 for intended use. In the words of the letter to Gram Peptides: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

Recipient	Letter date	What FDA cited
Prime Vitality, Inc. dba Prime Peptides	Dec 10, 2024	Instagram, Facebook and YouTube posts, including a "TESTIMONIALS" post about retatrutide weight loss.
Summit Research Peptides	Dec 10, 2024	"RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY" labels. FDA also reviewed the firm's Facebook page.
Xcel Research LLC	Dec 10, 2024	Claims phrased as effects on "research test subjects" still established intended human use.
USApeptide.com	Feb 26, 2025	Unapproved new drugs and misbranding (no adequate directions for use), with bacteriostatic water and insulin syringes sold alongside.
Gram Peptides	Mar 31, 2026	Website copy on weight, glucose and appetite. Bacteriostatic water sold alongside peptides, which FDA said shows intent for use "in combination for injection."
Prime Sciences	Mar 31, 2026	Coded product names, which FDA decoded ("GLP1-S" identified as semaglutide), and labels reading "laboratory research purposes only."
Wholesale Peptide	Jun 17, 2026	Disease claims such as "Prostamax for Enlarged Prostate," on products labeled "RESEARCH USE ONLY."
Royal Peptides LLC	Aug 24, 2026	Blog comparison posts, and bacteriostatic water marketed alongside a "peptide guide" and "peptide calculator."
TXP Innovations LLC dba Tex Peptides	Aug 24, 2026	Bacteriostatic water marketed "as a solvent for reconstituting your products."

Read together, the letters treat the whole business as the label. The Royal Peptides letter describes the calculator and guide as "resources that collectively provide the means to prepare an injectable drug for human administration." LegitScript, whose certification Google, Meta and TikTok accept, makes the same point to payment processors: "not for human consumption" language "is often a red flag rather than a legal protection" (LegitScript, October 2025).

We cover the letters in more depth in why "Research Use Only" does not protect a peptide business.

What does the FTC require from peptide and GLP-1 ad claims?

Substantiation

FTC guidance says claims about the health benefits or safety of drugs and other health products require "competent and reliable scientific evidence." As a general matter, that means "randomized, controlled human clinical testing" (Health Products Compliance Guidance, p. 11). The guidance says RCTs are "generally the type of substantiation that experts would require for health benefit claims," with limited exceptions, and that the advertiser should ask how the dosage and formulation advertised compare to what was studied.

Animal and in vitro studies: "without confirmation by human RCTs, they aren't sufficient to substantiate health-related claims" (p. 13).
Anecdotes and testimonials: customer experiences "are never sufficient to substantiate claims about the effects of a health product" (p. 13). The Endorsement Guides say the same: consumer endorsements "are not competent and reliable scientific evidence" (16 C.F.R. § 255.2(a)).

Qualifiers and disclaimers

Softening words do not rescue a claim the evidence does not support. The guidance says "it's not enough to say that the product 'may' have the claimed benefit or 'helps' achieve the claimed benefit," and that consumers tend to read "promising," "preliminary," "initial" or "pilot" as selling points rather than warnings (pp. 8 to 9). A disclosure also "can't directly contradict a claim" (p. 9). The fine print does not cancel the headline.

Implied claims and images

"Marketers can't suggest benefits, safety, or other characteristics about their product indirectly that they couldn't claim directly" (pp. 4 to 6). The FTC judges the "net impression" of the whole ad, including the product name, charts and images. Its examples include lab-coat imagery implying clinical proof and before-and-after images implying dramatic results. "Results not typical" does not cure a testimonial or photo showing atypical results (p. 26). Under the Endorsement Guides, an ad built on a consumer's experience should disclose what consumers can generally expect if the advertiser cannot show that experience is representative (§ 255.2(b)).

A paid or gifted endorser's connection to the brand must be disclosed clearly and conspicuously (16 C.F.R. § 255.5). Advertisers can be liable for misleading or unsubstantiated statements made through endorsements, even when the endorser is not (16 C.F.R. § 255.1(d)).

Penalties and a telehealth example

In April 2023 the FTC sent about 670 health-product marketers Notices of Penalty Offenses on substantiation. A company that knowingly does what those notices describe can face civil penalties, currently up to $53,088 per violation (16 C.F.R. § 1.98). The recipients were OTC-drug, homeopathic, supplement and functional-food marketers.

The clearest GLP-1 telehealth case is NextMed. In July 2025 the FTC charged the firm over weight-loss membership ads that left out the cost of the drug and required lab work, unsupported average weight-loss figures, fake reviews, and testimonials and before-and-after photos from non-customers. The final order in December 2025 required $150,000 for consumer refunds.

For claim-by-claim guidance, see what a peptide or GLP-1 clinic can and cannot say in ads.

What changed for compounded GLP-1 advertising in 2025 and 2026?

The shortages ended, and FDA turned to advertising. FDA declared the tirzepatide shortage resolved (final decision December 19, 2024) and the semaglutide shortage resolved (February 21, 2025). The compounding grace periods ended in 2025, the last on May 22, 2025, for 503B outsourcing facilities (FDA). Compounding still exists, but the shortage-based allowance to make copies has ended. FDA says that, at this time, it does not intend to act against a 503A compounder making essentially a copy of a commercially available drug if it fills four or fewer prescriptions of that copy in a calendar month, and it states plainly: "Compounded drugs are not approved by FDA."

Date	FDA action
Sep 9, 2025	Crackdown on deceptive drug advertising: thousands of letters and about 100 cease-and-desist letters.
Sep 9, 2025	Slendid received a warning letter citing "Clinically proven weight loss treatments" for compounded semaglutide and tirzepatide as implying the products are the same as an FDA-approved product. GLP-1 Solution received a warning letter citing compounded retatrutide as an unapproved new drug and its semaglutide and tirzepatide claims as misleading.
Feb 6, 2026	FDA statement: promotion may not claim compounded products are generic versions of, or the same as, FDA-approved drugs, may not say they use the same active ingredient, and may not say they are clinically proven to produce results.
Mar 3, 2026	Warning letters to 30 telehealth companies. The primary violations were claims implying sameness with approved products, and branding compounded drugs with the telehealth firm's name "without qualification, implying they are the compounder."

For telehealth operators, that means no "same active ingredient," "generic" or "clinically proven" near a compounded product, and no branding that implies the clinic made the drug.

Where BPC-157 stands (as of October 4, 2026)

Many articles still say BPC-157 is on FDA's "Category 2" list. That is out of date. FDA's Category 2 page now lists BPC-157 under bulk drug substances whose nominations were withdrawn. BPC-157 appears in no 503A category on FDA's category list updated May 14, 2026 and is not on the 503A bulks list. Under FDA's 503A framework, a bulk substance must have a USP or NF monograph, be a component of an FDA-approved drug, or be on the 503A bulks list, and a substance outside those routes is exposed to FDA's general enforcement policies. FDA's Pharmacy Compounding Advisory Committee met July 23 and 24, 2026 to discuss BPC-157 and other peptides, and FDA's briefing document proposed "not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List." No final FDA decision is posted. None of this makes "research" peptide sales lawful.

Why does the whole funnel need review, not just the ad?

Because every reviewer looks past the ad, starting with FDA. Google says it judges prescription-drug services "based on a number of factors, such as the content of your ads, site, or app," and "errs on the side of caution" with landing pages (Google). Meta's review "may include ... an ad's destination, like a landing page or website" (Meta). TikTok's weight and body-image rules apply to "ad content and landing pages" (TikTok). Mastercard requires acquirers to review their e-commerce merchants' websites on an ongoing basis (Mastercard, 2020 edition, § 7.2).

A useful review covers, at minimum:

Every ad, in every format and size.
The landing page and every page one click away, including the blog and FAQ.
Product names, vial and package art, and anything that implies who compounded the drug.
Social accounts, email and SMS, including posts by staff and paid creators.
What is sold alongside the product, and what the checkout allows without a prescription.

What do Google, Meta and TikTok allow for peptide and GLP-1 ads?

Policy pages change without notice. Every statement in this section was checked against the live page on October 4, 2026.

Platform	Prescription drugs and telehealth (US)	Unapproved products	Weight-loss creative
Google	Online pharmacies need LegitScript or NABP accreditation. Telemedicine providers need LegitScript. Both also need Google certification (Google).	Unapproved pharmaceuticals and supplements are prohibited, on a non-exhaustive list. Warn-first, at least 7 days before suspension (Google).	Google judges prescription-drug services from the ad, the site and the app, and errs on the side of caution with landing pages (Google).
Meta	To advertise prescription drugs, online pharmacies and telehealth providers need active LegitScript certification and Meta authorization, may target only the US, Canada or New Zealand, and must target 18+ (Meta). General telehealth promotion needs no authorization.	Unsafe substances, products or supplements are prohibited, "as determined by Meta at its sole discretion."	18+ targeting. No appearance attacks or pinched-fat close-ups (Meta).
TikTok	Prescription drugs may be allowed in the US and Canada only when regulator-approved and targeted 18+. Pharmacies need NABP, LegitScript or equivalent proof (TikTok).	No ads for drugs for enhancement, performance or weight loss (TikTok).	Restricted, not banned: 18+, healthy-lifestyle framing, no unrealistic or guaranteed results (TikTok).
YouTube	Ads follow Google's ad policies, including Healthcare and medicines (YouTube).	Content may not facilitate sale of prescription drugs without a prescription, including links to such sellers (YouTube).	YouTube ads follow Google's ad policies, as in the Google row (YouTube).

Three common claims that are wrong

"Google blacklists a domain for one peptide name." Google's unapproved-substances list names no peptide, and that policy is warn-first. In the US, prescription drug names such as semaglutide and tirzepatide may appear in ads and on landing pages, but keyword-targeting them requires Google certification (Google). The severe rule is different: offering prescription drugs without a prescription is an egregious violation, with suspension on detection, without warning, and no return to Google Ads (Google). A research-peptide checkout that sells semaglutide or retatrutide with no prescription falls on that side of the line.
"Meta bans before-and-after photos." As of October 2026, Meta's Health and Wellness policy (change log entry dated July 22, 2026) does not contain the side-by-side weight-loss before-and-after ban that older summaries quote. The FTC rules on implied claims and typical results still apply to any such image.
"TikTok bans weight-management ads." TikTok restricts them. It does prohibit ads for weight-loss drugs, and its US prescription-drug route requires regulator approval. In our reading, compounded drugs do not meet that condition as written, because they are not FDA-approved. TikTok does not address them by name.

Meta also bars ads that "assert or imply personal attributes," including medical conditions. "Do you have diabetes?" is its own example of what is not allowed (Meta). LegitScript's standards bar certified businesses from facilitating the prescribing or dispensing of unapproved medications, and advertising in apparent violation of a platform's terms can be grounds for denial or revocation (LegitScript).

The full platform breakdown is in Google, Meta and TikTok ad rules for peptide and GLP-1 clinics.

How should disclosures work in audio, video and display ads?

The FTC's test is outcome-based: a disclosure must be "difficult to miss (i.e., easily noticeable) and easily understandable by ordinary consumers" (16 C.F.R. § 255.0(f)). The Endorsement Guides and the FTC's .com Disclosures guidance describe what that means by channel.

Channel	What FTC guidance says
Audio (radio, podcast, streaming audio)	An audio claim gets an audio disclosure, delivered at a volume, speed and cadence ordinary consumers can easily hear and understand.
Video	A visual claim needs at least a visual disclosure. A claim made both visually and aloud needs the disclosure in both. Showing it in both at the same time is "more likely" to be clear. On-screen text must stay up long enough to notice, read and understand. Fleeting disclosures are not likely to be effective.
Display and web pages	Place the disclosure as close as possible to the claim, and judge its size, color and contrast against the rest of the page. A claim in written text needs a written disclosure, not one only in an audio or video clip.
Links and terms	Health and safety disclosures integral to a claim should not sit behind a hyperlink, and necessary disclosures should not be relegated to terms of use. Designs that need scrolling to find a disclosure should preferably be avoided, and if scrolling is needed, use cues.
Social and online	Disclosures should be unavoidable. A disclosure only on a profile page, or behind a "more" link, does not qualify (§ 255.0(g), Example 9).

Two rules that circulate are not real. No FTC rule requires a WCAG 4.5:1 contrast ratio for ad disclosures. The guidance names contrast as a factor, with no number. And no FDA or FTC rule sets a minimum type size for a "Research Use Only" statement.

How do payment processors and card networks treat peptide businesses?

Card-network rules reach marketing directly. Visa requires acquirers to keep cards from being used to buy "products that claim or imply a similar efficacy as prescription drugs, controlled substances, or recreational/street drugs, irrespective of claims of legality" (Visa Core Rules, § 1.9.2.1). Visa can permanently bar a merchant and its principals for entering illegal or brand-damaging transactions (§ 1.9.1.4).

Pharmacies: Visa classifies card-not-present pharmacies (MCC 5122 and 5912) as Tier 1 High-Integrity Risk merchants that must be registered with Visa, and NABP accreditation or LegitScript Healthcare Merchant Certification exempts a pharmacy from that registration (Visa Integrity Risk Program guide, 2023 guide). Visa's 2026 Core Rules name NABP for the same exemption, along with any other regulatory body Visa recognizes (Visa Core Rules). Mastercard requires acquirers to register card-not-present pharmacies and verify their legality, for example by a legal opinion or third-party accreditation (Mastercard, 2020 edition, § 9.4.3).
As of October 2026, Stripe prohibits "incorrectly labeled research chemicals" and treats telemedicine, online pharmacies and card-not-present prescription products as restricted businesses that need extra due diligence (Stripe). It requires preapproval for prescription peptides and assumes any peptide sold without a stated purpose is for human consumption (Stripe FAQ).
As of October 2026, Square's standard payment terms prohibit online pharmacies and pharmacy referral services that fulfill medication after a remote consultation (Square).
As of October 2026, PayPal requires pre-approval to sell prescription items and to offer telemedicine services (PayPal).

MATCH. If an acquirer terminates a merchant, the merchant can be added to Mastercard's MATCH system. Listings stay for five years, cover principal owners as well as the business, and most processors decline a listed business or owner (Stripe). Reason codes include 13 "Illegal Transactions" and 10 "Violation of Standards."

Merchant category codes. Visa requires acquirers to assign the MCC that most accurately describes the merchant's business (§ 1.5.1.11). Disguising what a business sells to get approved breaks processor terms and network rules, and miscoding has been prosecuted as part of a bank-fraud conspiracy: in 2021 a federal jury convicted two defendants of conspiracy to commit bank fraud in a scheme that applied incorrect MCCs to disguise marijuana transactions (U.S. Attorney, SDNY).

More on underwriting and MATCH in payment processing for peptide and telehealth businesses.

What does a compliant peptide marketing setup look like?

It runs through a licensed prescriber, because every rule above points the same way. FDA's letters target unapproved drugs sold for human use. Google treats offering prescription drugs without a prescription as egregious. LegitScript requires care by a licensed professional before any prescription. In a prescriber-led model the advertising promotes the clinical service, not a vial, claims stay within what the evidence and FDA allow, certification is in place before launch, and the checkout enforces the prescription.

LUKE's prescription-gated checkout is built for that last step: a clinic flags products as requiring a prescription, and a flagged product cannot be bought without an active, verified prescription, enforced at checkout and in the database. It is one control inside a clinic's own compliance program, not a substitute for one.

Pre-launch checklist for peptide and GLP-1 advertising

Confirm every prescription product is prescribed by a licensed clinician after an evaluation and dispensed by a licensed pharmacy.
Remove "Research Use Only," "not for human consumption" and coded product names. FDA's letters treat them as no defense.
For compounded drugs, remove "same active ingredient," "generic," "same as" and "clinically proven," and state who compounds the product where branding could imply the clinic does.
Match every health claim to evidence, which FTC guidance says will generally mean randomized, controlled human trials. Cut claims supported only by animal, in vitro or anecdotal evidence.
Check images and headlines for implied claims. For testimonials, disclose material connections and what patients can generally expect.
Put disclosures in the same medium as the claim, next to it, and long enough on screen to read. Do not rely on hyperlinks or terms of use for health and safety disclosures.
Obtain LegitScript certification and the platform's own certification or authorization before running prescription-drug ads on Google or Meta, and confirm 18+ targeting.
Review the landing page, blog, social, email and checkout with the same standard as the ad, and make the checkout enforce the prescription.
Disclose the business accurately to the payment processor and confirm the product category is permitted under its current terms.
Re-check platform policy pages before each launch and date the review.

Legal disclaimer: This article is for informational purposes only and does not constitute legal, regulatory, or compliance advice. FDA and FTC positions, platform advertising policies and payment-network rules change. Platform policies were checked on October 4, 2026. Consult qualified legal counsel before launching or changing advertising for peptide, hormone or GLP-1 services.

Run a Prescriber-Led Clinic on One Platform

LUKE gives telehealth clinics prescription-gated checkout for flagged products, intake links and a lead pipeline, and Stripe billing, built HIPAA-first with a Business Associate Agreement on every plan. If you also want help with advertising, see our advertising services.

Prescription-gated checkout Intake links and lead pipeline Stripe checkout and subscriptions A Business Associate Agreement with every plan

Book a consultation

Advertising and marketing services are provided by Ernesto Cullari Media LLC, LUKE's agency partner, under a separate agreement. They are not part of a LUKE software subscription.

Frequently Asked Questions

Does a "Research Use Only" label protect a peptide seller from FDA?

No. FDA's peptide warning letters from 2024 to 2026 say that research-use and not-for-human-use statements did not change the result when the seller's website showed the products were meant for human use. FDA judges intended use from objective evidence, including labeling claims, advertising and the circumstances of distribution, under 21 C.F.R. § 201.128. FDA's own "Research Use Only" labeling rule, 21 C.F.R. § 809.10(c), covers in vitro diagnostic products, not peptides.

Can a telehealth clinic advertise compounded semaglutide or tirzepatide?

A clinic can advertise its clinical services, but FDA said on February 6, 2026 that promotion may not call compounded drugs generic versions of, the same as, or the same active ingredient as FDA-approved drugs, or say they are clinically proven to produce results. On March 3, 2026 FDA announced warning letters to 30 telehealth companies over claims implying sameness with approved drugs or hiding who compounded the product. As of October 2026, Google and Meta also require LegitScript certification plus their own certification or authorization before a US telehealth provider can promote prescription drugs.

Does Google ban a website for mentioning BPC-157 or another peptide?

Not for a mention alone. As of October 2026, Google's list of unapproved substances names no peptide, although its catch-all clauses can reach an unapproved product marketed as safe or effective for a disease. That policy is warn-first, with at least seven days' notice before suspension. The severe rule is different: Google treats offering prescription drugs without a prescription as an egregious violation, with suspension on detection, without warning, and no return to Google Ads.

Did Meta ban before-and-after photos in weight-loss ads?

Not in its current policy. As of October 2026, Meta's Health and Wellness policy (change log entry dated July 22, 2026) no longer contains the side-by-side before-and-after ban that older summaries quote. It still bars weight-loss ads that attack a person's appearance or show close-ups of pinched fat, and it requires 18+ targeting. FTC guidance still applies: before-and-after images can convey implied claims that need substantiation, and "Results not typical" does not cure an atypical result.

What evidence does the FTC expect for a peptide health claim?

FTC staff guidance says health claims need competent and reliable scientific evidence, which as a general matter means randomized, controlled human clinical trials. Animal and in vitro studies are not enough without confirmation by human trials, and customer testimonials never substantiate a health claim. Qualifiers such as "may" or "helps" do not fix an unsupported claim, and a disclaimer cannot contradict the claim it sits next to.

What is the Mastercard MATCH list and why does it matter?

MATCH is a Mastercard system that acquirers check before signing a merchant. It holds information about merchants, and their principal owners, that another acquirer terminated. A listing stays on the system for five years, most processors decline a listed business or owner, and the reason codes include 13 "Illegal Transactions" and 10 "Violation of Standards".

Is BPC-157 on FDA's Category 2 list?

Not as of October 4, 2026. FDA's Category 2 page lists BPC-157 among substances whose nominations were withdrawn, it appears in no 503A category, and it is not on the 503A bulks list. FDA's July 2026 briefing document proposed not adding it to the 503A bulks list, and no final FDA decision is posted.